Rapamycin
also Rapamune, Sirolimus
Immune-suppressing drug, also called sirolimus
Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mammalian target of rapamycin (mTOR) kinase inhibitor that reduces the sensitivity of T cells and B cells to interleukin-2 (IL-2), inhibiting their activity.
Read “Sirolimus” on Wikipedia and its adverse effects · text from Wikipedia, CC BY-SA 4.0
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research 10
- Promotion of Hair Regrowth by Transdermal Dissolvable Microneedles Loaded with Rapamycin and Epigallocatechin Gallate Nanoparticles
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Enhancing hair regrowth using rapamycin-primed mesenchymal stem cell-derived exosomes
- Cutaneous Side Effects of Sports Supplements
- Mammalian target of rapamycin complex 1 (m TORC 1) may modulate the timing of anagen entry in mouse hair follicles
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Molecular pathways involved in hair follicle tumor formation: all about mammalian target of rapamycin?
- Clinical Application of Development of Nonantibiotic Macrolides That Correct Inflammation-Driven Immune Dysfunction in Inflammatory Skin Diseases
- Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for new hair growth
- Differential expression of phospho‐S6 in hair follicle tumors: Evidence of mammalian target of rapamycin pathway activation
- Case Report: Melanocyte-associated mTORC1-related molecular features in an atypical large congenital melanocytic naevus
- Synergistic magneto-electro-thermal biochemical cascade modulation enables rapid healing and functional restoration of infected wounds
- Emerging pharmacotherapies for androgenetic alopecia
- LHX2: a transcription factor in development, homeostasis, repair, and disease
- Angelica sinensis promotes thymic cortical regeneration in mice with acute thymic involution induced by short-term rapamycin treatment
- Folliculin: A surprising molecular brake in the human hair follicle
- Valproic acid boosts hair follicle stem cell resilience to oxygen-glucose deprivation through autophagy induction and AKT/mTOR suppression
- Preliminary Study on Platelet-Rich Plasma Enhancing Autophagy Level and Promoting Hair Growth in Androgenetic Alopecia Model Mice
- Role of UVA-driven cellular senescence via mTOR activation in dihydrotestosterone-induced hair loss in androgenetic alopecia mouse model
- Enhancing hair regrowth using rapamycin-primed mesenchymal stem cell-derived exosomes
Posts 2
- Does anyone have experience with Retrograde alopecia? Can’t seem to find any info on it.
- Posted this recently, but no reply, I wonder if people don’t like bad news?